|
| Trial registration number | Study type | Patient number | Blood derivatives | Conditions | End-point | Phase |
|
| NCT01089985 | Interventional | 10 | AS | Xerophthalmia | Efficacy and safety of AS. | Phase 1 |
|
| NCT01972438 | Randomized
Intervention
Double-blind | 44 | Autologous serum versus saline solution | HSCT patients with severe ocular GVHD | Treatment of severe chronic ocular GVHD in HSCT patients unresponsive to standard medical treatment. | Phase 1
Phase 2 |
|
| NCT01075347 | Randomized
Intervention Assignment
Single-blind | 165 | Human autoserum versus traditional medications (0.1% betamethasone, 0.3% gentamicin, and 0.4% tropicamide eye drops) | Corneal epithelial defect,
diabetic retinopathy,
penetrating keratoplasty | Corneal epithelial healing time by slit-lamp examination with fluorescein staining. | Phase 1 |
|
| NCT00681642 | Observational | 7 | Human autoserum versus cord blood serum | Corneal epithelial defect, dry eye syndrome | Wound healing, cell proliferation and migration by means of wound healing assay evaluation, MTS assay, and Boyden chamber migration assay. | Completed |
|
| NCT00442273 | Interventional
Nonrandomized
Double-blind | 48 | 20% autologous serum and umbilical cord serum eye drops | Severe dry eye syndrome | Therapeutic effect between autologous serum and umbilical cord serum eye drops in the treatment of severe dry eye syndrome. | Not provided |
|
| NCT00598299 | Observational
Prospective | 100 | Human autoserum versus cord blood serum | Corneal epithelial defect, dry eye syndrome | Corneal wound healing assay evaluation, MTS assay, and Boyden chamber migration assay | Completed |
|
| NCT01168375 | Intervention | 80 | Umbilical cord serum | Corneal epithelial defect following diabetic vitrectomy | Measurement of corneal epithelial defect in days 3, 5, 7, and 12 by slit lamp. | Phase 1 |
|
| NCT01016158 | Interventional
Randomized
Single-blind | NP | 20% umbilical cord serum eye drops | Recurrent corneal erosion | Efficacy 20% umbilical cord serum eye drops. | Completed |
|
| NCT01234623 | Randomized | 30 | Cord blood serum | GVHD, Sjogren’s Disease | Healing of corneal epithelial defects, ameliorating the painful subjective symptoms. | Phase 1 |
|
| NCT02291731 | Interventional
Single-blind | Not provided | 20% autologous serum eye drops and silicone-hydrogel contact lens (CLs) | Corneal diseases | Clinical effect of combination of topical 20% autologous serum eye drops and CLs in the treatment of recalcitrant PEDs and the recurrence rate of epithelial breakdown with or without continued use of autologous serum eye drops for 2 weeks after total reepithelialization. | Currently recruiting |
|
| NCT01122303 | Observational | 20 | 20% autologous serum eye drops | SJS, nonautoimmune dry eye | Comparisons of the concentrations of EGF, TGF-β1, TGF-β2, and fibronectin in 20% AS between SJS patients with dry eye and nonautoimmune dry eye patients. | Unknown |
|
| NCT00238862 | Randomized
single group Open label | 180 | Autologous serum 20% versus amniotic membrane transplantation | PED | Corneal reepithelialization, persistent corneal reepithelialization. | Completed |
|
| NCT02153515 | Single group
Open label | 60 | Autologous serum finger prick of blood | Dry eyes, PED, ulcers | Ulcers time healing (within 4 weeks)
Improving of corneal and conjunctival staining, Schirmer’s test, tear break-up time, or symptoms ocular comfort index questionnaire (dry eyes). | Phase 3 |
|
| NCT00779987 | Interventional
study
Double-blind | 12 | 20% autologous serum solution | Dry eye | Score reduction in the OSDI between patients treated with autologous serum and conventional artificial tears. | Phase 2 |
|
